Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USDFYE December
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026.
Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ACBM SEC filings page.
Acro Biomedical Co Ltd (ACBM) reported $0 in revenue
for fiscal year 2025.
This page shows its income statement, balance sheet, cash flow statement, and key financial ratios.
View 11 years of annual fundamentals and quarterly data, with year-over-year
growth rates and compound annual growth rates (CAGR).
All figures are derived from SEC filings (10-K and 10-Q reports).
Rhea AIACBMFY2025
Development spending, not gross margin, dominates the economics as revenue contracts and cash conversion reverses.
In FY2021, R&D intensity reached 4.4x revenue while operating cash flow was $299K; after revenue contracted in FY2022, operating cash flow turned negative at -$147K. Cash generation therefore did not track the scale of development investment, indicating that the positive earlier cash result was not a durable operating pattern.
Revenue contraction was the main visible pressure: revenue fell from $1.2M in FY2021 to $659K in FY2022. Gross margin remained about 21% across both years, so the deterioration came mainly through volume rather than a reported margin reset.
Balance-sheet flexibility narrowed as the current ratio fell from 7.7x to 3.3x between FY2021 and FY2022. Liabilities also rose from 15.4% to 29.3% of assets, while gross margin stayed near 21% and operating cash flow reached -$147K; the modest gross contribution was not yet funding the broader cost base.
Financial Health Signals
Financial health score not available
Acro Biomedical Co Ltd does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Acro Biomedical Co Ltd generated $0 in revenue in Q2 2026.
EPS (Diluted)
$0.00
Acro Biomedical Co Ltd earned $0.00 per diluted share (EPS) in Q2 2026.
EBITDA
Not reported for Q2 2026.
Net Income
Not reported for Q2 2026.
Cash & Balance Sheet
Cash & Debt
$4K
YoY+13930.8%
QoQ-5.8%
5Y CAGR-55.8%
Acro Biomedical Co Ltd held $4K in cash as of Q2 2026; long-term debt is not reported for that period.
Shares Outstanding
60M
YoY0.0%
QoQ0.0%
Acro Biomedical Co Ltd had 60M shares outstanding in Q2 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.
Free Cash Flow
Not reported for Q2 2026.
Dividends Per Share
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
ACBM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: EBITDA.
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, EPS (Basic).
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ACBM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ACBM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ACBM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: FCF Margin.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$387K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Acro Biomedical Co Ltd (ACBM) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What is Acro Biomedical Co Ltd's earnings per share (EPS)?
Acro Biomedical Co Ltd (ACBM) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What are Acro Biomedical Co Ltd's total assets?
Acro Biomedical Co Ltd (ACBM) had $14K in total assets as of fiscal year 2025, including both current and long-term assets.
How many shares does Acro Biomedical Co Ltd have outstanding?
Acro Biomedical Co Ltd (ACBM) had 60M shares outstanding as of fiscal year 2025.
What is Acro Biomedical Co Ltd's current ratio?
Acro Biomedical Co Ltd (ACBM) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Why is Acro Biomedical Co Ltd's debt-to-equity ratio negative or not reported?
Acro Biomedical Co Ltd (ACBM) has negative shareholder equity of -$387K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
